Published in Br J Cancer on November 01, 1986
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer (1998) 1.16
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. Br J Cancer (1992) 1.00
Cinnarizine and flunarizine as radiation sensitisers in two murine tumours. Br J Cancer (1988) 0.92
Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br J Cancer (1997) 0.77
A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse. Br J Cancer (1976) 3.42
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys (1986) 1.87
Vascular reactions of normal and malignant tissues in vivo. IV. The effect of peripheral hypotension on transplanted tumors. J Natl Cancer Inst (1951) 1.57
Changes of oxygen tension in tumours induced by vasoconstrictor and vasodilator drugs. Acta radiol (1962) 1.35
EFFECT OF BREATHING HIGH PRESSURE OXYGEN UPON TISSUE OXYGEN TENSION IN RAT AND MOUSE TUMOURS. Acta Radiol Ther Phys Biol (1963) 1.16
Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer (1984) 1.11
EFFECT OF 5-HYDROXYTRYPTAMINE AND CYPROHEPTADINE ON TUMOUR BLOOD FLOW; ESTIMATION BY RATE OF COOLING AFTER MICROWAVE DIATHERMY. Acta Radiol Ther Phys Biol (1965) 1.08
Blood flow and oxygenation of tumors in mice. II. Effects of vasodilator drugs. Cancer (1967) 1.04
The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br J Cancer (1986) 0.99
RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol (1986) 0.98
Selective drug-induced reduction of blood flow in tumor transplants. Int J Radiat Oncol Biol Phys (1985) 0.91
The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys (1986) 0.90
Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069. Int J Radiat Oncol Biol Phys (1984) 0.87
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res (1999) 1.79
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys (1989) 1.71
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer (1985) 1.57
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys (1987) 1.48
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer (1985) 1.47
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 1.32
Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer (1999) 1.30
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer (1989) 1.19
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res (1998) 1.19
The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res (1995) 1.18
Tumour blood flow changes induced by application of electric pulses. Eur J Cancer (1999) 1.17
Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer (1993) 1.17
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol (1991) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol (1998) 1.09
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer (2010) 1.07
Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol (1996) 1.06
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer (1998) 1.05
Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342. Br J Cancer (1990) 1.04
Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer (2001) 1.03
Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res (1987) 1.01
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer (2000) 0.99
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res (2001) 0.99
Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys (1989) 0.98
Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer (1995) 0.98
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer (1990) 0.97
Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed (1999) 0.97
The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res (2001) 0.97
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res (1990) 0.96
Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer (1991) 0.96
Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol (1999) 0.95
Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer (2000) 0.95
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res (1997) 0.94
Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys (1994) 0.94
The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer (1995) 0.94
Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Radiother Oncol (1996) 0.93
The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int J Radiat Oncol Biol Phys (1992) 0.93
The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother Oncol (1994) 0.93
Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res (1995) 0.93
Cell sorting with Hoechst or carbocyanine dyes as perfusion probes in spheroids and tumors. Methods Cell Biol (1990) 0.92
Enhancement of chlorambucil cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res (1994) 0.92
Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys (1994) 0.92
The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer (1997) 0.91
The influence of microenvironment on the cytotoxicity of TNF [symbol: see text] vitro. Int J Radiat Oncol Biol Phys (1994) 0.91
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des (1998) 0.91
The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys (1986) 0.90
Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys (1998) 0.90
Photofrin uptake by murine macrophages. Cancer Res (1991) 0.89
Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res (1997) 0.89
Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur J Cancer (1991) 0.89
The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer (1999) 0.88
Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol (1994) 0.88
Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl (1996) 0.87
Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Exp Physiol (1997) 0.87
Effect of carbogen breathing on tumour microregional blood flow in humans. Radiother Oncol (1996) 0.86
Inhibition of intracellular pH control and relationship to cytotoxicity of chlorambucil and vinblastine. Br J Cancer Suppl (1996) 0.86
The comparative effects of the NOS inhibitor, Nomega-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int J Radiat Oncol Biol Phys (1998) 0.85
The response of mouse epidermis to fractionated doses of pi mesons. Int J Radiat Oncol Biol Phys (1987) 0.84
Human tumor blood flow is enhanced by nicotinamide and carbogen breathing. Cancer Res (1997) 0.83
Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol (1997) 0.83
The use of blood flow modifiers to improve the treatment response of solid tumors. Radiother Oncol (1991) 0.83
Combination therapy of pions and SPG (Sonifilan, Schizophyllan), a biological response modifier for mouse tumor systems. Int J Radiat Oncol Biol Phys (1990) 0.83
The effect of nicotinamide on microregional blood flow within tumours assessed using laser Doppler probes. Acta Oncol (1995) 0.83
Involvement of oxygen free radicals in ischaemia-reperfusion injury to murine tumours: role of nitric oxide. Free Radic Res (1998) 0.82
Oxygen and nitroreductase-dependent binding of AF-2 in spheroids and murine tumors. Int J Radiat Oncol Biol Phys (1986) 0.82
Cytotoxic effect of tumour necrosis factor -alpha on sarcoma F cells at tumour relevant oxygen tensions. Acta Oncol (1995) 0.82
Chemosensitization by misonidazole in CCNU-treated spheroids and tumours. Br J Cancer (1987) 0.81
Cytotoxicity of RSU 1069 in spheroids and murine tumors. Int J Radiat Oncol Biol Phys (1987) 0.80
Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer (1996) 0.80
Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res (1997) 0.80
The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother Oncol (1990) 0.80
Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA. Br J Cancer Suppl (1996) 0.80
Immune reaction induced by X-rays and pions and its stimulation by schizophyllan (SPG). Br J Cancer Suppl (1996) 0.80
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer Suppl (1996) 0.80
Blood flow modification in the SCCVII tumor: effects of 5-hydroxytryptamine, hydralazine, and propranolol. Int J Radiat Oncol Biol Phys (1992) 0.79
Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy. Biomed Biochim Acta (1989) 0.79
Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia. Br J Cancer (2001) 0.79
Studies on the protection against misonidazole-induced toxicity by antiinflammatory agents. Adv Prostaglandin Thromboxane Leukot Res (1983) 0.79
Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. Int J Radiat Oncol Biol Phys (1998) 0.78
Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma. Br J Cancer Suppl (1996) 0.78
Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor. J Cardiovasc Pharmacol (1995) 0.78
Enhancement of mitomycin-C cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res (1993) 0.78
Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. Int J Radiat Oncol Biol Phys (1992) 0.78
Detection of microregional fluctuations in erythrocyte flow using laser Doppler microprobes. Adv Exp Med Biol (1996) 0.77
Nicotinamide reduces tumour interstitial fluid pressure in a dose- and time-dependent manner. Br J Radiol (1997) 0.77
The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia (1997) 0.77
The effects of nicotinamide plus carbogen or pions for microscopic SCCVII tumors. Oncol Rep (1999) 0.77
The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol (1994) 0.77
Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats. Int J Cancer (1997) 0.77
The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells. Br J Cancer (1993) 0.77
Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake. Br J Cancer (1995) 0.77